ライフサイエンスコーパス: tingling

1 uently reported were ear pain, headache, and tingling.

2 who received oxaliplatin more often reported tingling (29% v 8%; P = .001), numbness (17% v 5%; P = .

3 versus 4%), and weakness (58% versus 2%) and tingling (54% versus 4%) in the arms or legs.

4 pain (97%; 34 patients), burning (97%; 34), tingling (97%; 34), pruritus (83%; 29), allodynia (89%;

5 lement for muscle building, induces itch and tingling after consumption, but the underlying molecular

6 plexus-related symptoms all consisting of C8 tingling and all arising after multiple days of support.

7 the compound most responsible for the unique tingling and buzzing sensations produced by Szechuan pep

8 using visual analogue scales (VAS) for pain, tingling and discomfort.

9 l transient reports of mild neck pain, scalp tingling and headache that were extinguished upon follow

10 The most common side effect was a mild tingling and itching sensation during stimulation (100%)

11 occasional body weakness, burning sensation, tingling and numbness of the feet, fatigue, loss of libi

12 otentially disabling symmetric chronic pain, tingling and poor balance.

13 he genital region, such as pain, discomfort, tingling, and burning sensations, have rarely been repor

14 Patients with complaints of numbness, tingling, and dysesthesias in the toes and feet are freq

15 hysician with a 3-month history of numbness, tingling, and faint violaceous discoloration of the tips

16 ted to mild and transient headache, fatigue, tingling, and nausea.

17 The symptoms of chronic pain, tingling, and numbness are generally attributed to small

18 rden of neurologic symptoms (pain, numbness, tingling, and walking disability) and worse quality of l

19 Numbness and tingling are more prominent chronic neuropathic symptoms

20 lude amenorrhea, morning sickness, tender or tingling breasts, and, after 8 weeks' gestational age, a

21 patients, red eyes by 28 (67%) patients, and tingling by 30 (71%) patients; no patient experienced vi

22 he presence of sensory abnormalities such as tingling, correlate with the impact of FM, and that peop

23 t discomfort (eg, moderate foot numbness and tingling for 22.1% FLOX v 4.6% FULV).

24 Symptoms like pain, tingling, glare and red eyes disappear in less than 48 h

25 or throat sores, itchy skin, and numbness or tingling in hands or feet) were absent or mild in most p

26 el syndrome is characterized by numbness and tingling in the thumb and the index, middle, and radial

27 ts such as transient flushing, tightness, or tingling in the upper body in 25% of patients.

28 /drying, fatty texture, dairy mouthfeel, and tingling/irritation" sensations.

29 e effects included nausea, loss of appetite, tingling, L'hermitte's sign, intermittent hallucinations

30 gums; trouble with eyes; pain, numbness, or tingling of hands or feet; and diarrhea or loose or wate

31 RPV1 expression and the VAS scores for pain, tingling or discomfort.

32 the chemoradiotherapy group reported severe tingling or numbness compared with 11 (6%) of 170 patien

33 Poor balance or coordination, tingling or weakness in the arms or legs, and numbness i

34 (n=10), isolated slurred speech, hemisensory tingling, or diplopia (n=8), and non-focal events (n=4).

35 sensory input, often perceived as a burning, tingling, or stinging sensation, is well known to affect

36 the prickly ash plant family, induces robust tingling paresthesia by activating a subset of somatosen

37 cellular and molecular mechanisms underlying tingling paresthesia that accompanies peripheral neuropa

38 cooling with neuropathic descriptors such as tingling/pins and needles.

39 sounds can produce an intense somatosensory tingling sensation in a patient with a thalamic lesion.

40 nthoxylum, Szechuan pepper, produce a strong tingling sensation in the mouth.

41 s." For tacrolimus ointment, "Explanation of tingling sensation"(as a side effect) was the most frequ

42 Those reporting a numbness and tingling severity score of 3 or greater for at least 10

43 riants, transient confusion, and hemisensory tingling symptoms as TNAs in uncertain territory.

44 11%), trouble opening jars or bottles (11%), tingling toes/feet (10%), and trouble walking stairs or

45 They also more often reported tingling toes/feet (29% v 14%; P = .0127) compared with

46 For chronic neurotoxicity, tingling was the most severe symptom, followed by numbne

47 he sensory neuropathy symptoms, numbness and tingling were more prominent than was shooting or burnin